Solid Biosciences (SLDB) said it will provide a corporate update at the J.P. Morgan Healthcare Conference later Wednesday outlining its expanded clinical-stage pipeline and 2025 objectives.
Among the highlights from the presentation include its SGT-003 for Duchenne muscular dystrophy and SGT-212 for Friedreich's ataxia, Solid said. It said SGT-003 continued to be well tolerated in the first four patients dosed in an ongoing trial.
The company said it has resources to fund its key strategic priorities into 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.